CRISPR therapy towards an HIV cure. (8th November 2019)

• Record Type: Journal Article
• Authors: Herrera-Carrillo, Elena; Gao, Zongliang; Berkhout, Ben
• Is Part Of: Briefings in functional genomics. Volume 19:Number 3(2020)
• Page Start: 201
• Page End: 208
• Publication Date: 2019-11-08
• Subjects: RNA interference -- CRISPR-Cas -- HIV -- gene therapy -- lentiviral vector -- polymerase III promoter; Genomics -- Methodology -- Periodicals; Genomics -- Technological innovations -- Periodicals; 572.86072
• DOI: 10.1093/bfgp/elz021
• Languages: English
• ISSNs: 2041-2649

Abstract

Abstract: Tools based on RNA interference (RNAi) and the recently developed clustered regularly short palindromic repeats (CRISPR) system enable the selective modification of gene expression, which also makes them attractive therapeutic reagents for combating HIV infection and other infectious diseases. Several parallels can be drawn between the RNAi and CRISPR-Cas9 platforms. An ideal RNAi or CRISPR-Cas9 therapeutic strategy for treating infectious or genetic diseases should exhibit potency, high specificity and safety. However, therapeutic applications of RNAi and CRISPR-Cas9 have been challenged by several major limitations, some of which can be overcome by optimal design of the therapy or the design of improved reagents. In this review, we will discuss some advantages and limitations of anti-HIV strategies based on RNAi and CRISPR-Cas9 with a focus on the efficiency, specificity, off-target effects and delivery methods.